Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ACP3 | P15309 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13626301 | 0.87 | SRC (0.46) | L3MBTL1 | |
| SCHEMBL9980574 | 0.87 | SRC (0.46) | L3MBTL1 | |
| SCHEMBL11573233 | 0.83 | PTGS2 (0.59) | PTGS2MAPTSMN1; SMN2ACP3FFAR1 | |
| SCHEMBL17524311 | 0.78 | PTGS2 (0.81) | PTGS2MAPTSMN1; SMN2ACP3CYP1A2 | |
| SCHEMBL30785017 | 0.78 | PTGS2 (0.57) | PTGS2MAPTSMN1; SMN2ACP3FFAR1 | |
| SCHEMBL11729113 | 0.77 | PTGS2 (0.47) | PTGS2MAPTSMN1; SMN2FFAR1GAA | |
| SCHEMBL6187748 | 0.76 | PTGS2 (0.60) | PTGS2MAPTSMN1; SMN2ACP3FFAR1 | |
| Acetic Acid SCHEMBL9809790 | 0.75 | PTGS2 (0.64) | PTGS2MAPTSMN1; SMN2ACP3FFAR1 | |
| SCHEMBL4558922 | 0.73 | PTGS2 (0.52) | PTGS2MAPTSMN1; SMN2FFAR1L3MBTL1 | |
| SCHEMBL12861259 | 0.73 | PTGS2 (0.52) | PTGS2MAPTSMN1; SMN2ACP3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008124756-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | BDKRB1, BDKRB2, HPGDS | PTGS2 87/4885MAPT 4116/4885SMN1; SMN2 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.